PRINCETON, N.J.--(BUSINESS WIRE)--Agile Therapeutics, Inc., a pharmaceutical development company specializing in women’s healthcare products, today announced study initiation and dosing of the first patient in the Company’s pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile’s lead contraceptive patch. AG200-15 is designed to effectively deliver a low dose of estrogen (ethinyl estradiol (EE)) in combination with levonorgestrel (LNG). The patch is applied once weekly for three weeks followed by a patch-free week.
